Abbott today announced positive long-term results for the company's innovative Absorb Bioresorbable Vascular Scaffold (BVS). Three-year results from 101 patients in the second stage of the ABSORB trial were presented ...
Read more
October 18, 2012 10:34 am by Frost, Peter | 0 Comments
Abbott Laboratories on Wednesday laid off 550 workers across several business units and said it plans to cut "several hundred" additional workers in 2013.About 100 of the layoffs were in ...
Read more
Current medical news from today, including Emergent BioSciences rebounds after Abbott pulls the plug on cancer drug partnership, searching for a cure for the hangover, and Avastin stabilizes ovarian cancer ...
Read more
November 29, 2011 11:35 am by Frank Vinluan | 0 Comments
A GlaxoSmithKline (NYSE:GSK) cancer drug program will be developed with a new companion diagnostic from Abbott (NYSE:ABT) as GSK moves to broaden its reach in personalized medicine.Abbott recently announced it ...
Read more
As Medtronic prepares to begin the first U.S. trial of a low-glucose suspense system, and as diabetes device companies, researchers and advocates look to the U.S. Food and Drug Administration ...
Read more
Current medical news from today, including Abbott Labs splits, European court says research that destroys human embryos can't be patented, and questions about the Da Vinci surgery robot. ...
Read more
October 5, 2011 7:19 am by Brandon Glenn | 0 Comments
Abbott Vascular’s Ferolyn Powell talks about the company’s MitraClip technology, which is used to treat a common heart valve condition called mitral regurgitation.The MitraClip device is designed to reduce significant ...
Read more
Abbott (NYSE:ABT) enrolled its first patients in a Japanese trial of the Absorb bioresorbable vascular scaffold.The Absorb stent opens clogged blood vessels and provides support to restore blood flow, and ...
Read more
Abbott Laboratories (NYSE:ABT) and Boston Scientific Corp. (NYSE:BSX) came out as the big players in the U.S. drug-eluting stent market, together staking claim to more than half of all DES ...
Read more
There’s no pleasing some people. Abbott (NYSE:ABT) shares were down on Wall Street today, despite the health care products giant reporting strong second-quarter sales and earnings figures ’ including a ...
Read more
An unknown bandit made off with a trailer shipment of Abbot Laboratories’ (NYSE:ABT) blood glucose monitoring products, and the company is working with law enforcement officials to get it back.In ...
Read more
Abbott had solid earnings to report, but problems in the pharmaceuticals portion of its business are triggering job cuts. About 2 percent of the company's global workforce will be let ...
Read more
Abbott Laboratories Inc. (NYSE:ABT) goes before a Food & Drug Administration panel today, seeking to expand the indication for its RX Acculink carotid artery stent. ...
Read more
December 20, 2010 8:43 am by Mary Vanac | 0 Comments
As medical schools wrestle with how to keep drug companies from corrupting their faculties, Stanford University often is lauded for its tough stance. But a ProPublica investigation found that more ...
Read more
